Steven Scheufler, MD
Family Medicine · Wellington, KSNPI 1447231428
Payments from drug & device makers
Across 220 payments — averaging $12.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$516
- Novo Nordisk$386
- Amgen$259
- Johnson & Johnson$211
- Sanofi-aventis U.S. LLC$173
- Merck$163
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,725100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $516 |
| Novo Nordisk | 29 | $386 |
| Amgen | 18 | $259 |
| Johnson & Johnson | 25 | $211 |
| Sanofi-aventis U.S. LLC | 13 | $173 |
| Merck | 16 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $157 |
| Boehringer Ingelheim | 17 | $141 |
| Pfizer | 20 | $134 |
| AbbVie(2 entities) | 8 | $104 |
| Astellas Pharma US Inc | 6 | $84 |
| Amarin Pharma, Inc. | 5 | $69 |
| Sunovion Pharmaceuticals Inc. | 10 | $59 |
| Teva Pharmaceuticals USA, Inc. | 4 | $58 |
| Shire North American Group Inc | 2 | $31 |
| Novartis | 2 | $30 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Radius Health, Inc. | 2 | $29 |
| Insulet Corporation | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Bayer | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,725 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $128,710 |
| MounjaroTirzepatide | 82 | $88,110 |
| OzempicSemaglutide | 75 | $77,042 |
| XareltoRivaroxaban | 40 | $39,957 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $37,773 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $31,612 |
| MyrbetriqMirabegron | 58 | $30,841 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $30,426 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 34 | $29,156 |
| FarxigaDapagliflozin Propanediol | 49 | $27,895 |
| GlyxambiEmpagliflozin/Linagliptin | 17 | $27,039 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $25,112 |
| RybelsusSemaglutide | 18 | $24,275 |
| JardianceEmpagliflozin | 32 | $23,914 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $23,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $134 | $135,102161 claims |
| Novo NordiskOzempic, Rybelsus | $386 | $101,31793 claims |
| Boehringer IngelheimGlyxambi, Jardiance, Synjardy Xr, Tradjenta | $141 | $81,03489 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta | $516 | $63,790110 claims |
| Johnson & JohnsonXarelto, Invokana | $211 | $49,03552 claims |
| MerckJanumet Xr, Belsomra | $163 | $33,91445 claims |
| Astellas Pharma US IncMyrbetriq | $84 | $30,84158 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $173 | $15,53026 claims |
| NovartisEntresto | $30 | $11,44715 claims |
| AbbVieSynthroid | $104 | $5,95765 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $157 | $4,14411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Wellington
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.